See more : Coal India Limited (COALINDIA.BO) Income Statement Analysis – Financial Results
Complete financial analysis of ScinoPharm Taiwan, Ltd. (1789.TW) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of ScinoPharm Taiwan, Ltd., a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
- Greenland Hong Kong Holdings Limited (0337.HK) Income Statement Analysis – Financial Results
- Elbit Medical Technologies Ltd (EMTC-M.TA) Income Statement Analysis – Financial Results
- Zhejiang Zomax Transmission Co., Ltd. (603767.SS) Income Statement Analysis – Financial Results
- All Things Mobile Analytic Inc. (ATMH) Income Statement Analysis – Financial Results
- Ribo Fashion Group Co., Ltd. (603196.SS) Income Statement Analysis – Financial Results
ScinoPharm Taiwan, Ltd. (1789.TW)
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Website: https://www.scinopharm.com
About ScinoPharm Taiwan, Ltd.
ScinoPharm Taiwan, Ltd., together with its subsidiaries, researches and develops, produces, and sells cGMP active pharmaceutical ingredients (API) to pharmaceutical companies in Taiwan, the United States, Europe, India, rest of Asia, and internationally. The company offers custom synthesis services for biochemistry molecules, such as peptides and nucleic acids; generic API manufacturing services; and outsourcing services. It also provides CRAM services, such as chemistry skill, analytical and regulatory, chemical process development, clinical drug substance, and consulting services for the development and manufacturing of clinical, small-scale, and commercial-stage APIs and intermediates. In addition, the company develops peptide synthesis technologies. Further, it develops and manufactures western medicines and other chemical materials, albumin medicines, oligonucleotide medicines, injections, and new small molecule drugs, as well as provides biological technology services and technical services. It has a strategic alliance with Baxter International Inc. to develop, manufacture, and commercialize of antiemetic drug in chemotherapy for cancer. ScinoPharm Taiwan, Ltd. was incorporated in 1997 and is headquartered in Tainan City, Taiwan.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 3.19B | 3.26B | 2.76B | 3.08B | 2.89B | 3.52B | 3.52B | 4.03B | 3.96B | 4.10B | 5.09B | 4.57B | 3.95B | 3.89B | 3.81B |
| Cost of Revenue | 1.97B | 2.01B | 1.48B | 1.77B | 1.72B | 1.98B | 1.97B | 2.22B | 2.28B | 2.50B | 2.55B | 2.26B | 1.97B | 1.86B | 1.91B |
| Gross Profit | 1.22B | 1.25B | 1.28B | 1.32B | 1.18B | 1.54B | 1.55B | 1.81B | 1.68B | 1.60B | 2.54B | 2.31B | 1.98B | 2.03B | 1.90B |
| Gross Profit Ratio | 38.17% | 38.32% | 46.36% | 42.73% | 40.67% | 43.77% | 44.08% | 44.80% | 42.39% | 39.06% | 49.97% | 50.59% | 50.19% | 52.27% | 49.81% |
| Research & Development | 357.74M | 271.26M | 305.95M | 245.63M | 238.37M | 313.21M | 314.28M | 279.58M | 324.21M | 415.89M | 417.88M | 303.02M | 291.45M | 302.19M | 327.87M |
| General & Administrative | 364.17M | 406.53M | 532.23M | 525.42M | 513.80M | 524.05M | 531.16M | 488.14M | 445.70M | 447.54M | 538.72M | 565.81M | 390.72M | 340.12M | 312.09M |
| Selling & Marketing | 179.65M | 167.34M | 153.57M | 170.90M | 157.17M | 146.93M | 145.76M | 169.97M | 157.04M | 177.70M | 188.44M | 185.35M | 168.81M | 169.09M | 93.39M |
| SG&A | 543.83M | 573.88M | 685.79M | 696.32M | 670.96M | 670.98M | 676.92M | 658.11M | 602.74M | 625.24M | 727.16M | 751.16M | 559.54M | 509.22M | 405.48M |
| Other Expenses | 0.00 | 18.26M | 835.00K | -29.46M | 53.89M | 12.30M | -7.03M | -21.56M | 61.45M | 62.40M | 35.72M | 110.99M | 41.46M | 60.88M | -7.83M |
| Operating Expenses | 901.50M | 845.14M | 991.74M | 941.96M | 909.34M | 984.19M | 991.20M | 937.69M | 926.95M | 1.04B | 1.15B | 1.05B | 850.99M | 811.40M | 733.35M |
| Cost & Expenses | 2.87B | 2.86B | 2.47B | 2.71B | 2.63B | 2.97B | 2.96B | 3.16B | 3.21B | 3.54B | 3.69B | 3.31B | 2.82B | 2.67B | 2.65B |
| Interest Income | 53.63M | 22.12M | 19.38M | 27.41M | 37.98M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 29.80M | 17.91M | 4.21M | 3.58M |
| Interest Expense | 9.15M | 7.91M | 6.55M | 15.17M | 55.69M | 80.17M | 76.63M | 36.12M | 9.02M | 4.14M | 7.92M | 29.00K | 108.00K | 4.42M | 32.65M |
| Depreciation & Amortization | 461.17M | 439.47M | 381.53M | 393.20M | 408.72M | 405.82M | 432.54M | 444.84M | 482.52M | 471.10M | 447.52M | 363.27M | 347.63M | 366.83M | 374.29M |
| EBITDA | 819.15M | 885.47M | 690.49M | 766.65M | 729.67M | 964.23M | 984.47M | 1.29B | 1.23B | 1.09B | 1.85B | 1.74B | 1.48B | 1.58B | 1.51B |
| EBITDA Ratio | 25.71% | 27.13% | 25.00% | 24.87% | 25.22% | 27.71% | 28.00% | 32.04% | 32.73% | 26.29% | 36.63% | 37.53% | 37.95% | 39.78% | 39.82% |
| Operating Income | 314.49M | 446.01M | 308.96M | 373.45M | 320.96M | 558.33M | 558.96M | 868.28M | 749.70M | 559.44M | 1.40B | 1.26B | 1.13B | 1.22B | 1.17B |
| Operating Income Ratio | 9.87% | 13.66% | 11.18% | 12.11% | 11.10% | 15.84% | 15.90% | 21.54% | 18.95% | 13.65% | 27.47% | 27.54% | 28.67% | 31.42% | 30.58% |
| Total Other Income/Expenses | 34.35M | -8.05M | -6.67M | -17.00M | -2.01M | -67.79M | -83.66M | -57.68M | 53.18M | 42.77M | 11.01M | 116.85M | 57.04M | -26.77M | -62.53M |
| Income Before Tax | 348.84M | 437.96M | 302.29M | 358.51M | 265.05M | 490.54M | 475.30M | 810.60M | 802.88M | 602.21M | 1.41B | 1.37B | 1.14B | 1.20B | 1.10B |
| Income Before Tax Ratio | 10.95% | 13.42% | 10.94% | 11.63% | 9.16% | 13.92% | 13.52% | 20.11% | 20.30% | 14.70% | 27.68% | 30.00% | 28.72% | 30.73% | 28.94% |
| Income Tax Expense | 61.78M | 84.74M | 58.82M | 76.44M | 48.40M | 47.56M | 52.94M | 151.91M | 167.92M | 118.07M | 135.11M | 201.25M | 174.00M | 155.84M | 64.26M |
| Net Income | 287.06M | 353.22M | 243.47M | 282.07M | 216.66M | 442.98M | 422.37M | 658.69M | 634.97M | 484.14M | 1.27B | 1.17B | 959.36M | 1.04B | 1.04B |
| Net Income Ratio | 9.01% | 10.82% | 8.81% | 9.15% | 7.49% | 12.57% | 12.01% | 16.34% | 16.05% | 11.81% | 25.03% | 25.60% | 24.27% | 26.73% | 27.30% |
| EPS | 0.36 | 0.45 | 0.31 | 0.36 | 0.27 | 0.56 | 0.53 | 0.83 | 0.81 | 0.61 | 1.61 | 1.48 | 1.24 | 1.44 | 1.51 |
| EPS Diluted | 0.36 | 0.45 | 0.31 | 0.36 | 0.27 | 0.56 | 0.53 | 0.83 | 0.80 | 0.61 | 1.61 | 1.48 | 1.24 | 1.44 | 1.51 |
| Weighted Avg Shares Out | 790.74M | 790.74M | 790.74M | 790.74M | 790.74M | 790.74M | 790.74M | 790.74M | 790.74M | 790.74M | 790.74M | 790.74M | 771.34M | 721.95M | 690.95M |
| Weighted Avg Shares Out (Dil) | 792.33M | 792.68M | 792.28M | 792.19M | 792.08M | 793.08M | 792.58M | 793.72M | 792.19M | 790.75M | 790.77M | 790.78M | 771.38M | 721.97M | 690.95M |
Source: https://incomestatements.info
Category: Stock Reports